As a research center embedded within Kaiser Permanente’s large and dynamic health care system, our investigators have a unique opportunity to apply scientific expertise to real-world clinical problems, translate findings into practice, and share what we learn with the broader community.
Dr. Vivienne Hau is a medical and surgical vitreoretinal specialist at the Kaiser Permanente Riverside Medical Center and is the vice area research chair for Riverside on the Southern California Permanente Medical Group’s Regional Research Committee. She is a clinical assistant professor with the Kaiser Permanente Bernard J. Tyson School of Medicine. She founded and directs Kaiser Permanente’s largest ophthalmology prospective clinical trial program. She is the principal investigator of ...
Over the years, clinical trials have led to amazing advances in treatment—even cures—for devastating illnesses. William Towner, MD, FACP, FIDSA, regional physician director for clinical trials, describes how trials at Kaiser Permanente contribute to the development of more effective and safer treatments for diseases such as HIV, hepatitis C, cancer, and more. (2:15)
A behavioral and public health scientist, Taynara Formagini, PhD, MSc, is a postdoctoral research fellow in the Department of Research & Evaluation. Her work focuses on preventing cardiovascular and chronic diseases among racial and ethnic minorities and socioeconomically disadvantaged populations through a combination of intervention research and epidemiology. What inspired you to pursue research? I’m ...
Kaiser Permanente research found that breast cancer survivors have a higher risk of developing other cancers if they have other preexisting health conditions, such as high blood pressure and diabetes. “Preexisting health conditions are common in people diagnosed with cancer and what we’ve learned with this study is that comorbidities — experiencing multiple illnesses or ...
Maheen Humayun, PhD, MPH, is an infectious disease epidemiologist and postdoctoral research fellow in the Department of Research & Evaluation. Prior to joining Kaiser Permanente, Dr. Humayun worked as an HIV Cluster Detection and Response Fellow at the Centers for Disease Control and Prevention. In that role, she analyzed national HIV surveillance data to detect rapid ...
About 16% of breast cancer survivors continued to use opioid pain medications after their cancer treatment was complete, a new Kaiser Permanente study showed. The study also found that risk of death was 84% higher among these survivors who continued to use opioids. The study was published in June 2025 in JNCI Cancer Spectrum. “The ...
Growing numbers of patients are diagnosed with cancer between the ages of 15 and 39. These younger cancer patients can have complex health needs after their cancer treatment and should receive health care that includes screening for new cancers, addresses potential issues related to their treatment, and emphasizes general preventive care. Researchers at Kaiser Permanente ...
The latest IMPACT newsletter, which focuses on research from Kaiser Permanente Southern California, is now available! It features 11 stories on our groundbreaking research, links to over a dozen media stories, and a Q&A with a health economics investigator.
Our behavioral scientists focus on research that has the potential to reduce disease risk by identifying modifiable risk factors and encouraging health-promoting behaviors. Faculty members have expertise in the following areas: adverse childhood experiences, cancer, chronic disease prevention and screening, diet and nutrition, mental health, obesity, physical activity, sedentary behavior, social determinants of health, and weight loss surgery and interventions.
The behavioral research portfolio includes intervention studies as well as qualitative and quantitative studies. The division also supports recruitment and other activities of the Kaiser Permanente Research Bank in Southern California.